Gastric Cancer - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 982 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H1 2017, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 14, 70, 77, 7, 74, 12 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 4, 8 and 1 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 8
Gastric Cancer - Overview 9
Gastric Cancer - Therapeutics Development 10
Gastric Cancer - Therapeutics Assessment 40
Gastric Cancer - Companies Involved in Therapeutics Development 58
Gastric Cancer - Drug Profiles 131
Gastric Cancer - Dormant Projects 935
Gastric Cancer - Discontinued Products 943
Gastric Cancer - Product Development Milestones 946
Appendix 954

List of Tables

Number of Products under Development for Gastric Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Products under Development by Companies, H1 2017 (Contd..14), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Gastric Cancer - Pipeline by 3SBio Inc, H1 2017
Gastric Cancer - Pipeline by AB Science SA, H1 2017
Gastric Cancer - Pipeline by AbbVie Inc, H1 2017
Gastric Cancer - Pipeline by AbGenomics International Inc, H1 2017
Gastric Cancer - Pipeline by Abion Inc, H1 2017
Gastric Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
Gastric Cancer - Pipeline by ADC Therapeutics Sarl, H1 2017
Gastric Cancer - Pipeline by Aduro BioTech Inc, H1 2017
Gastric Cancer - Pipeline by Advaxis Inc, H1 2017
Gastric Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
Gastric Cancer - Pipeline by Agenus Inc, H1 2017
Gastric Cancer - Pipeline by Almac Discovery Ltd, H1 2017
Gastric Cancer - Pipeline by Alteogen Inc, H1 2017
Gastric Cancer - Pipeline by Ambrx Inc, H1 2017
Gastric Cancer - Pipeline by amcure GmbH, H1 2017
Gastric Cancer - Pipeline by Amgen Inc, H1 2017
Gastric Cancer - Pipeline by ANP Technologies Inc, H1 2017
Gastric Cancer - Pipeline by Antikor Biopharma Ltd, H1 2017
Gastric Cancer - Pipeline by arGEN-X BV, H1 2017
Gastric Cancer - Pipeline by Array BioPharma Inc, H1 2017
Gastric Cancer - Pipeline by Asana BioSciences LLC, H1 2017
Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2017
Gastric Cancer - Pipeline by Astellas Pharma Inc, H1 2017
Gastric Cancer - Pipeline by AstraZeneca Plc, H1 2017
Gastric Cancer - Pipeline by Athenex Inc, H1 2017
Gastric Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2017
Gastric Cancer - Pipeline by Bayer AG, H1 2017
Gastric Cancer - Pipeline by BeiGene Ltd, H1 2017
Gastric Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2017
Gastric Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017
Gastric Cancer - Pipeline by Bionovis SA, H1 2017
Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Gastric Cancer - Pipeline by Boston Biomedical Inc, H1 2017
Gastric Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
Gastric Cancer - Pipeline by Camel-IDS NV, H1 2017
Gastric Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2017
Gastric Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017
Gastric Cancer - Pipeline by Celgene Corp, H1 2017
Gastric Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017
Gastric Cancer - Pipeline by Cellectar Biosciences Inc, H1 2017
Gastric Cancer - Pipeline by Celltrion Inc, H1 2017
Gastric Cancer - Pipeline by Celon Pharma SA, H1 2017
Gastric Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2017
Gastric Cancer - Pipeline by Curaxys SL, H1 2017
Gastric Cancer - Pipeline by Cytori Therapeutics Inc, H1 2017
Gastric Cancer - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Gastric Cancer - Pipeline by Debiopharm International SA, H1 2017
Gastric Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
Gastric Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017
Gastric Cancer - Pipeline by Eli Lilly and Company, H1 2017
Gastric Cancer - Pipeline by EOS Biosciences Inc, H1 2017
Gastric Cancer - Pipeline by Erytech Pharma SA, H1 2017
Gastric Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2017
Gastric Cancer - Pipeline by Exelixis Inc, H1 2017
Gastric Cancer - Pipeline by F-star Biotechnology Ltd, H1 2017
Gastric Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Gastric Cancer - Pipeline by Five Prime Therapeutics Inc, H1 2017
Gastric Cancer - Pipeline by Frost Biologic Inc, H1 2017
Gastric Cancer - Pipeline by Galena Biopharma Inc, H1 2017
Gastric Cancer - Pipeline by Genelux Corp, H1 2017
Gastric Cancer - Pipeline by Genentech Inc, H1 2017
Gastric Cancer - Pipeline by Gilead Sciences Inc, H1 2017
Gastric Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
Gastric Cancer - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
Gastric Cancer - Pipeline by GlycoNex Inc, H1 2017
Gastric Cancer - Pipeline by Glycotope GmbH, H1 2017
Gastric Cancer - Pipeline by Green Cross Corp, H1 2017
Gastric Cancer - Pipeline by Halozyme Therapeutics Inc, H1 2017
Gastric Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Gastric Cancer - Pipeline by Horizon Pharma Plc, H1 2017
Gastric Cancer - Pipeline by Hutchison China MediTech Ltd, H1 2017
Gastric Cancer - Pipeline by Ignyta Inc, H1 2017
Gastric Cancer - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017
Gastric Cancer - Pipeline by Immunomedics Inc, H1 2017
Gastric Cancer - Pipeline by Incyte Corp, H1 2017
Gastric Cancer - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Gastric Cancer - Pipeline by Inspyr Therapeutics Inc, H1 2017
Gastric Cancer - Pipeline by Insys Therapeutics Inc, H1 2017
Gastric Cancer - Pipeline by Intezyne Technologies Inc, H1 2017
Gastric Cancer - Pipeline by Ipsen SA, H1 2017
Gastric Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017
Gastric Cancer - Pipeline by Johnson & Johnson, H1 2017
Gastric Cancer - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
Gastric Cancer - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2017
Gastric Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
Gastric Cancer - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017
Gastric Cancer - Pipeline by LegoChem Biosciences Inc, H1 2017
Gastric Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2017
Gastric Cancer - Pipeline by MacroGenics Inc, H1 2017
Gastric Cancer - Pipeline by MaxiVAX SA, H1 2017
Gastric Cancer - Pipeline by Mebiopharm Co Ltd, H1 2017
Gastric Cancer - Pipeline by MedImmune LLC, H1 2017
Gastric Cancer - Pipeline by Merck & Co Inc, H1 2017
Gastric Cancer - Pipeline by Merck KGaA, H1 2017
Gastric Cancer - Pipeline by Mersana Therapeutics Inc, H1 2017
Gastric Cancer - Pipeline by Merus NV, H1 2017
Gastric Cancer - Pipeline by Mirati Therapeutics Inc, H1 2017
Gastric Cancer - Pipeline by Molecular Partners AG, H1 2017
Gastric Cancer - Pipeline by Molecular Targeting Technologies Inc, H1 2017
Gastric Cancer - Pipeline by MolMed SpA, H1 2017
Gastric Cancer - Pipeline by NanoCarrier Co Ltd, H1 2017
Gastric Cancer - Pipeline by Novartis AG, H1 2017
Gastric Cancer - Pipeline by Novogen Ltd, H1 2017
Gastric Cancer - Pipeline by OBI Pharma Inc, H1 2017
Gastric Cancer - Pipeline by Oncobiologics Inc, H1 2017
Gastric Cancer - Pipeline by Oncolys BioPharma Inc, H1 2017
Gastric Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H1 2017
Gastric Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Gastric Cancer - Pipeline by Opsona Therapeutics Ltd, H1 2017
Gastric Cancer - Pipeline by Panacea Biotec Ltd, H1 2017
Gastric Cancer - Pipeline by Patrys Ltd, H1 2017
Gastric Cancer - Pipeline by Pfizer Inc, H1 2017
Gastric Cancer - Pipeline by Pharma Mar SA, H1 2017
Gastric Cancer - Pipeline by Plexxikon Inc, H1 2017
Gastric Cancer - Pipeline by Puma Biotechnology Inc, H1 2017
Gastric Cancer - Pipeline by Redx Pharma Plc, H1 2017
Gastric Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017
Gastric Cancer - Pipeline by Rgenix Inc, H1 2017
Gastric Cancer - Pipeline by Rhizen Pharmaceuticals SA, H1 2017
Gastric Cancer - Pipeline by Richter Gedeon Nyrt, H1 2017
Gastric Cancer - Pipeline by Samumed LLC, H1 2017
Gastric Cancer - Pipeline by Sanofi, H1 2017
Gastric Cancer - Pipeline by Selecta Biosciences Inc, H1 2017
Gastric Cancer - Pipeline by Sequella Inc, H1 2017
Gastric Cancer - Pipeline by Shionogi & Co Ltd, H1 2017
Gastric Cancer - Pipeline by Simcere Pharmaceutical Group, H1 2017
Gastric Cancer - Pipeline by Sorrento Therapeutics Inc, H1 2017
Gastric Cancer - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
Gastric Cancer - Pipeline by Stelic Institute & Co Inc, H1 2017
Gastric Cancer - Pipeline by Supratek Pharma Inc, H1 2017
Gastric Cancer - Pipeline by SynCore Biotechnology Co Ltd, H1 2017
Gastric Cancer - Pipeline by Synovo GmbH, H1 2017
Gastric Cancer - Pipeline by Synthon Holdings BV, H1 2017
Gastric Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
Gastric Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2017
Gastric Cancer - Pipeline by Takis Srl, H1 2017
Gastric Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H1 2017
Gastric Cancer - Pipeline by Transgene SA, H1 2017
Gastric Cancer - Pipeline by United BioPharma Inc, H1 2017
Gastric Cancer - Pipeline by Vaxon Biotech, H1 2017
Gastric Cancer - Pipeline by Viracta Therapeutics Inc, H1 2017
Gastric Cancer - Pipeline by XuanZhu Pharma Co Ltd, H1 2017
Gastric Cancer - Pipeline by Zymeworks Inc, H1 2017
Gastric Cancer - Dormant Projects, H1 2017
Gastric Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
Gastric Cancer - Dormant Projects, H1 2017 (Contd..2), H1 2017
Gastric Cancer - Dormant Projects, H1 2017 (Contd..3), H1 2017
Gastric Cancer - Dormant Projects, H1 2017 (Contd..4), H1 2017
Gastric Cancer - Dormant Projects, H1 2017 (Contd..5), H1 2017
Gastric Cancer - Dormant Projects, H1 2017 (Contd..6), H1 2017
Gastric Cancer - Dormant Projects, H1 2017 (Contd..7), H1 2017
Gastric Cancer - Discontinued Products, H1 2017
Gastric Cancer - Discontinued Products, H1 2017 (Contd..1), H1 2017
Gastric Cancer - Discontinued Products, H1 2017 (Contd..2), H1 2017